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Abstract Mitochondrial tRNALeu(UUR) mutation m.3302A>
G is associated with respiratory chain complex I deficiency
and has been described as a rare cause of mostly adult-onset
slowly progressive myopathy. Five families with 11 patients
have been described so far; 5 of them died young due to
cardiorespiratory failure. Here, we report on a segregation
study in a family with an index patient who already presented
at the age of 18 months with proximal muscular hypotonia,
abnormal fatigability, and lactic acidosis. This early-onset
myopathy was rapidly progressive. At 8 years, the patient is
wheel-chair bound, requires nocturnal assisted ventilation, and
suffers from recurrent respiratory infections. Severe complex I
deficiency and nearly homoplasmy for m.3302A>G were
found in muscle. We collected blood, hair, buccal swabs and
muscle biopsies from asymptomatic adults in this pedigree
and determined heteroplasmy levels in these tissues as well as
OXPHOS activities in muscle. All participating asymptomatic
adults had normal OXPHOS activities. In contrast to earlier
reports, we found surprisingly little variation of heteroplasmy
levels in different tissues of the same individual. Up to 45%
mutation load in muscle and up to 38% mutation load in other
tissues were found in non-affected adults. The phenotypic
spectrum of tRNALeu(UUR) m.3302A>G mutation seems to be
wider than previously described. A threshold of more than
45% heteroplasmy in muscle seems to be necessary to alter
complex I activity leading to clinical manifestation. The
presented data may be helpful for prognostic considerations
and counseling in affected families.
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Introduction
Human mitochondrial function requires precise excision of
tRNAs from the precursor transcript by specific
endonucleases for the 3′- and 5′-terminal nucleotides. The
CCA-terminus, which is required for aminoacylation and
thus for protein synthesis, is then added by a tRNA
nucleotidyl transferase (Schurer et al. 2001). In the
transcript of the human mitochondrial genome, the gene
MT-TL1 for tRNALeu(UUR) is located between the genes for
16S rRNA and ND1, which encode the subunit 1 of
respiratory chain complex I.
Mitochondrial (mt) tRNALeu(UUR) is a hot spot for
mtDNA mutations linked with inherited severe neuromuscu-
lar diseases. Mutation m.3302A>G is located in the
aminoacyl stem of tRNALeu(UUR), 2 nucleotides away from
the 3′-terminal nucleotide (Wallace and Lott 2009). This
mutation leads to reduced efficiency of 3′-end cleavage
(Levinger et al. 2004). A substantial accumulation of RNA19,
an unproprocessed RNA intermediate including mt-16S
rRNA, mt-tRNALeu(UUR) and MTND1, was found in patient
muscle. Mutation m.3302A>G leads to increased steady-
state levels, and increased stability of RNA19 and decreased
mt-tRNALeu(UUR)levels with unchanged stability consistent
with a defect in RNA19 processing (Maniura-Weber et al.
2006). The quality and/or quantity of ND1 mRNA seems to
be affected, resulting in reduced OXPHOS complex I
activity. Important qualitative differences in the processing
of the precursor were found when comparing muscle to skin
fibroblasts. In muscle, processing appears to occur first at the
5′-end of the tRNA, generating 16S rRNA plus a tRNA +
ND1 intermediate. In fibroblasts, processing occurs at the
3′-end of the tRNA, generating a 16S rRNA + tRNA
intermediate (Bindoff et al. 1993).
The m.3302A>G mutation has so far been described in 11
individuals of 5 families (Table 1) (Watmough et al. 1990;
Bindoff et al. 1993; Shoffner et al. 1993; van den Bosch et
al. 2004; Hutchison et al. 2005). Slowly progressive adult-
onset myopathy and exercise intolerance are the main
clinical symptoms. Five patients (4 of the same family) died
at young age (10–35 years) due to cardiorespiratory failure.
Van den Bosch et al. described two affected individuals in
the same family (mother and son). The mother had a
mutation load of 76% in muscle, whereas other tissues
showed lower levels (58% in hair, 52% in fibroblasts and
33% in blood). The son had 96% of mutation in muscle,
80% in hair, 60% in fibroblasts and 62% in blood. After a
stay at high altitude, the son died of cardiac arrhythmia. The
authors concluded that the m.3302A>G mutation can lead to
fatal cardiorespiratory failure, likely triggered by low
environmental oxygen pressure and exercise and that
patients with a higher mutation load have a higher risk for
cardiorespiratory failure (van den Bosch et al. 2004).
Watmough et al. reported on a 22-year-old affected
woman with positive family history of muscle disease.
Her mother had died aged 35 from cardiorespiratory
failure. Postmortem investigation had shown accumula-
tion of neutral lipids and subsarcolemmal aggregation of
mitochondria in skeletal muscle. A sister, aged 15, and a
brother, aged 10, had also died of cardiorespiratory
failure secondary to undiagnosed muscle disease
(Watmough et al. 1990). Hutchison et al. described 4
patients (1 sporadic case and 3 patients of the same
family) with adult onset. Mutation loads in these patients
varied from >95% in muscle to 17% in lymphocyte DNA.
Besides the typical clinical features they observed hearing
loss, recurrent headaches, ptosis, progressive external
ophthalmoplegia and depression in their patients
(Hutchison et al. 2005). The youngest patient so far
described with the m.3302A>G mutation had a normal
development until 5 years of age when, over 1 year, a
rapidly progressive myopathy with proximal muscle
weakness, shoulder girdle atrophy, and profound weak-
ness of neck flexion and extension became evident
(Shoffner et al. 1993).
Variable age of onset and lack of data on the
correlation between mutation load and phenotype, as well
as variations of heteroplasmy levels in different tissues,
complicate prognostic predictions in relatives of affected
patients. No reliable test for prenatal diagnosis can be
offered to female carriers of this mutation. Thus, genetic
and reproductive counseling is particularly difficult in
these families.
In this article, we describe a girl carrying the tRNALeu(UUR)
mutation m.3302A>G at high levels in different tissues with
very early onset and rapidly progressive myopathy. In
addition, we present a segregation study of mutation loads
in different tissues and OXPHOS activities in M. quadriceps
biopsies in family members.
Materials and methods
Patients
Written informed consent was obtained from all partici-
pating family members. Blood, hair and buccal swab were
sampled in the index patient, her mother, aunt, uncle and
grandmother. Biopsy of the M. quadriceps in the index
patient and the three individuals of the parent generation
enabled OXPHOS assays and determination of mutation
load in muscle. Skin biopsy was only performed in the
index patient for investigation of mutation load, OXPHOS
assays and oxygen consumption in fibroblasts. Besides the
index patient, all study participants were in good health
and did not show any signs of myopathy.
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Case report on index patient
The girl was first referred to our clinic at the age of 4 years
with a history of increasing muscular weakness since the age
of 18 months when she began to walk. On examination, she
showed normal psychomotor development. She had proximal
muscle weakness. Her walking distance was limited to 100 m.
She had marked neck extensor weakness with a drop-head
syndrome after holding her head up for a few minutes and a
positive Gowers sign. She climbed stairs using the ramp.
Deep tendon reflexes were present. She suffered from
recurrent episodes of obstructive bronchitis and otitis media.
During the following years, the patient showed rapid
progression of muscular hypotonia. By the age of 5 years,
she wore a neck brace all day long but her walking distance
was stable. At age 6 years, weakness progressed and she
was only able to walk very short distances and otherwise
used an electric wheel-chair. She was able to continue
school part-time with special supports (computer, adapted
desk). At 7 years, nocturnal assisted ventilation was started
due to episodes of desaturation. She continued to have
frequent bronchitis necessitating respiratory assistance
during these infections.
She is the first child of non-consanguineous parents of
Swiss (mother) and Algerian (father) origin. Her younger
brother (presently 6 years old) is asymptomatic. There is no
positive family history. Neurological examination of the
mother at age 36 years was normal.
Laboratory investigation showed metabolic acidosis
(pH 7,319, bicarbonate 16,9 mM, BE –8,0 mM), elevated
fasting serum pyruvate (218 μM), lactate (5,8 mM) and
β-hydroxybutyrate (355 μM) that paradoxically increased
in the postprandial state (pyruvate 325 μM, lactate
8,06 mM and β-hydroxybutyrate 607 μM). Organic acids
analysis in urine revealed elevation of several Krebs
cycle intermediates: fumarate, malate, 2-oxoglutarate, cis-
aconitate and isocitrate. There was no hypoglycemia or
biochemical signs of liver affection. ECG and echocardi-
ography and brain MRI were normal, with no increased
lactate at spectroscopy. Histology of M. quadriceps showed
slight variation in fiber size, striking subsarcolemmal
accumulation of mitochondria, ragged-red fibers, neutral
lipid deposits and diffuse overexpression of succinate
dehydrogenase in some fibers. The suspicion of a mito-
chondrial disorder was confirmed by analysis of the
oxidative phosphorylation (OXPHOS) in M. quadriceps
showing complex I deficiency (see “Results”). Molecular
analysis of mtDNA extracted from M. quadriceps revealed
the tRNALeu(UUR) m.3302A>G mutation using revised
Cambridge Reference Sequence (rCRS) of the Human
Mitochondrial DNA as reference sequence (GenBank
NC_012920 gi:251831106) (Andrews et al. 1999).
A therapeutic trial with administration of coenzyme Q10
(6,6 mg/kg/day) and riboflavin (5,3 mg/kg/day) over a
period of 3 months did not show any clinical effect and
plasma lactate remained unchanged. Under ketogenic diet,
stable ketosis was difficult to obtain due to repetitive
severe acidosis. Our patient tolerated a maximal lipid to
protein + carbohydrate ratio of 2:1. The effect of the
ketogenic diet was monitored by standardized evaluation
of muscle strength and no improvement was observed after
4 months. At present, she is 8 years old, on a low-
Table 1 Overview of patients with mutation m.3302A>G in tRNALeu
(UUR). Family I: Patients 1–4 (Watmough et al. 1990; Bindoff et al.
1993). Family II: Patient 5 (Shoffner et al. 1993). Family III: Patients 6
and 7 (van den Bosch et al. 2004). Family IV: Patient 8 (Hutchison et al.
2005). Family V: Patients 9–11 (Hutchison et al. 2005). Family VI:
Patient 12 is the index patient described in this article. Known mutation
loads are given for muscle (M), fibroblasts (F), hair (H), blood (B),
breast tissue (Ma) and buccal swab (BS)
Patient Family Sex Age of onset
(years)
Age of death
(years)
Cardiorespiratory
failure
Mutation load
1 I F 18 22 + M homoplasmy
2 I (mother) F Not known 35 + Not done
3 I (sister) F Not known 15 + Not done
4 I (brother) M Not known 10 + Not done
5 II ? 5 Alive – Not done
6 III F 40 Alive – M 76% , F 52%, H 58%, B 33%, Ma 67%
7 III (son) M 15 34 + (altitude) M 96%, F 60%, H 80%, B 62%
8 IV M 32 Alive – M>95%
9 V F 31 Alive – B 18%, BS 37%
10 V (sister) F 26 Alive – B>80%
11 V (cousin) F 27 Alive – B 17%
12 VI F 1 ½ Alive – M 98%, F 83%, H 98%, B 97%, BS 91%
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carbohydrate diet, and takes high-dose bicarbonates in
order to compensate the lactic acidosis.
DNA extraction
Total genomic DNA was extracted from buccal swabs and
hairs (QIAamp DNA Mini Kit; Qiagen), from blood
(Nucleon BACC Genomic DNA Extraction Kit; GE
Healthcare) and from muscle and fibroblasts (proteinase K
and digestion buffer; Upadhyaya et al. 1984).
Fluorescent PCR and enzyme restriction
A fluorescent PCR (1,5 ng DNA, 22 cycles) of the region
of interest was generated from the diverse tissues of the
patient and relatives, using the primers 5′ TAC TTC ACA
3
3
267 bp223 bp117 bp
mutated DNA wild-type DNA undigested DNA
Patient, not digested
Patient
Mother
Aunt
Uncle
a
b
c
d
e
Fig. 1 Results of capillary elec-
trophoresis obtained after PCR
amplification (a) and DdeI di-
gestion of DNA extracted from
blood (b–e). a Patient, undi-
gested, shows a peak at 267 bp,
corresponding to the size of the
full amplicon. b Patient,
digested, with a big 117 bp peak
(mutated) and a small 223 bp
peak (wt). The percentage of
heteroplasmy is calculated by
dividing the mutant peak area by
the total wild-type and mutant
peak areas, as for b :
3296=3296þ 360 ¼ 0:9 ¼
90% mutant heteroplasmy. c
Mother. d Aunt. e Uncle
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AAG CGC CTT CC 3′ (forward) and 5′ VIC-GGG CCT
TTG CGT AGT TGT AT 3′ (reverse, fluorescent) (van den
Bosch et al. 2004). PCR amplification was performed using
an Applied Biosystems Taq polymerase under the following
conditions: 95°C/5′; 95°C/30″; 56°C/30″; 72°C/45″;
72°C/7′; 22 cycles. The mutation m.3302A>G creates a
DdeI restriction site. The percentage heteroplasmy of the
m.3302A>G mutation was determined by digestion with a
mutation-specific restriction enzyme (DdeI, NEB). In the
absence of the mutation, the digestion yields two fragments
(44 and 223 bp), the largest being fluorescently labeled.
Digestion in the presence of the mutation yields three
fragments (44, 106, and 117 bp) of which the 117-bp
fragment is fluorescently labeled.
Capillary electrophoresis
The fragments obtained were separated on capillary
electrophoresis (ABI Prism 3100 Genetic analyzer) and
analyzed using the Genemapper software version 4.0
(Applied Biosystems). The percentage of heteroplasmy
was calculated by dividing the mutant peak area by the
total wild-type and mutant peak areas. The small N+1
peaks visible on some electropherograms are most likely
the result of a residual activity of the Taq polymerase
during the digestion, and the consequent addition of an
A on some fragments (Fig. 1). Every sample was
investigated at least in triplicates, except for hairs
(duplicates).
Patient Normal range (n=26)
Complex I 0.01/0.02 0.11–0.29
Complex II 0.14 0.14–0.36
Complex III 0.61 0.54–1.16
Complex IV 1.02 0.51–1.44
Complex V 0.60 0.17–0.55
Citrate synthase (mU/mg protein) 348 70–224
Table 2 OXPHOS assays in M.
quadriceps of the index patient.
Respiratory chain complex ac-
tivities are expressed as mU/mU
citrate synthase
B:   97% ± 1
BS: 91% ± 1
F:    83% ± 5
H:   98% ± 0
M :  98% ± 1
mtDNA mutation A3302G
OXPHOS: Normal
1938
1962 1964 1970
2001 2002
B:   3% ± 3
BS: 5% ± 3
H:   1% ± 0
M :  5% ± 2
B:   20% ± 7
BS: 18% ± 8
H:   23% ± 2
M :  18% ± 4
B:   35% ± 6
BS: 38% ± 9
H:   26% ± 4
M :  45% ± 8
B:   10% ± 2
BS: 8%   ± 2
H:   10% ± 2
OXPHOS: Normal OXPHOS: Normal
OXPHOS: 
complex I  10% in muscle
72% in fibroblastes
Fig. 2 Family pedigree indicat-
ing age, mutation load (± SD)
for m.3302A>G in blood (B),
buccal swab (BS), fibroblasts
(F), hair (H) and muscle (M) as
well as results of OXPHOS
analysis in M. quadriceps
biopsies and fibroblasts
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Cell culture
Primary fibroblast cultures were established from skin biopsy
and cultured in minimal essential medium (MEM) supple-
mented with 10% fetal calf serum, 4 mmol/L L-glutamine,
2 µmol/L uridine, 1 µmol/L sodium pyruvate, 50 U/ml
penicillin, and 50 µg/ml streptomycin at 37°C under standard
conditions.
OXPHOS assays
Isolation of mitochondria, preparation of skeletal muscle
homogenates (600 g supernatants) were performed as
described (Rustin et al. 1994; Birch-Machin and Turnbull
2001). The activities of the individual respiratory chain
complexes and the mitochondrial matrix marker enzyme
citrate synthase were measured spectrophotometrically
with a UV-1601 spectrophotometer (Shimadzu) using
1-ml sample cuvettes thermostatically maintained at 30°
C in skeletal muscle homogenates and isolated mitochon-
dria according to Birch-Machin and Turnbull (2001).
Values were estimated by the difference in activity levels
measured in the presence and absence of specific
inhibitors and are expressed relative to the mitochondrial
marker enzyme citrate synthase (mU/mU citrate synthase),
that was determined as described (Shepherd and Garland
1969).
Oxygen consumption
Oxygen consumption in fibroblasts was determined at 37°C
using the OROBOROS oxygraph (Innsbruck, Austria).
Fibroblasts were harvested, resuspended in Mitochondrial
Respiration Medium MiR05 (Renner et al. 2003), and
permeabilized by digitonin (10 μg/106 cells). The rates of
respiration (expressed in pmol O2 s
−1 10−6 cells) were
determined in the presence of 2 mM ADP and different
combinations of substrates and inhibitors: 10 mM pyruvate/
2 mM malate; 10 mM succinate/0.5 mM rotenone; 4 mM
ascorbate/0.5 mM TMPD. Measurements of oxygen
consumption by ascorbate/TMPD represent KCN (1 mM)-
sensitive values in the presence of 12.5 mM antimycin A.
Results
Mutation load
In the index patient, the tRNALeu(UUR) m.3302A>G
mutation was found at levels >90% in blood, buccal swab,
hair ,and muscle. Only in fibroblasts was the mutation load
significantly lower with 83% (Fig. 2). In accordance with
mitochondrial inheritance, the mutation was detectable in
all tested individuals. The grandmother, mother, aunt, and
uncle of the patient are asymptomatic and show a mean
mutant load of around 10, 40, 5, and 20% respectively
(Fig. 2). It is interesting to notice that we found little
variation of heteroplasmy in different tissues of the same
individual.
OXPHOS analysis
In skeletal muscle of the index patient, we found a marked
deficiency of complex I activity (about 10% residual
Patient Normal range (n=23)
Complex I 0.18/0.17 0.19–0.40
Complex II 0.29 0.10–0.45
Complex III 0.42 0.27–0.87
Complex IV 0.58 0.41–0.94
Complex V 0.10 0.10–0.34
Citrate synthase (mU/mg protein) 211 84–445
Table 3 OXPHOS assays in
skin fibroblasts of the index
patient. Respiratory chain com-
plex activities are expressed as
mU/mU citrate synthase
Respiratory substrates Patient Normal range (n=21)
Pyruvate/malate 26 32–67
Succinate/rotenone 32 29–82
Ascorbate/TMPD (CIV) 48 30–69
Respiratory control ratios
RCR (state3/state4) (Pyruvate/malate) 3.7 4.2–12.7
RCR (state3/state4) (Succinate/rotenone) 4.4 3.9–11.4
Table 4 Oxygen consumption
in permeabilized fibroblasts of
the index patient. Respiratory
rates are expressed in pmol O2
s−1 10−6 cells. The respiratory
control ratio (RCR) is defined as
the ratio of state 3 (in the
presence of ADP) to state 4 (in
the absence of ADP) respiratory
rates
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activity compared to the lowest control value), while the
other activities were in the range of the controls (Table 2).
In skin fibroblasts, the activity of complex I was only
slightly below the control range (Table 3). The slightly
reduced oxygen consumption with complex I substrates as
well as the slightly reduced respiratory control ratio (RCR)
with pyruvate and malate as substrates is in agreement with
the results of the respiratory chain complex activities
(Table 4). OXPHOS analyses of M. quadriceps biopsies in
the mother, aunt and uncle revealed normal results for all
parameters (Fig. 2).
Discussion
Mitochondriopathies are usually multi-system disorders
(Zeviani and Carelli 2007). The fact that this mutation
leads to an isolated muscle disease can probably be
explained by its effect on 3′-end cleavage and different
time courses of tRNA processing in different tissues
(Bindoff et al. 1993; Levinger et al. 2004). As muscle is
the principally affected organ, one would postulate that a
higher mutation load in muscle should correlate with a
more severe phenotype. This does not seem to be the case
as several patients with very high mutation load in muscle
have been described with variable degree of clinical
severity (Bindoff et al. 1993; van den Bosch et al. 2004;
Hutchison et al. 2005). Thus, individual modifying factors
may influence disease expression.
The diagnosis of an individual with the tRNALeu(UUR)
m.3302A>G mutation confronts affected families, clinicians,
and genetic counselors with a lot of unsolved questions. Due
to variable age of onset (infancy to adulthood) and variable
degree of symptoms (severe myopathy to mild exercise
intolerance), genetic counseling and clinical prognosis is
very hazardous. In relatives with mild muscle weakness, it
might be difficult to distinguish between disease-related and
psychological/subjective symptoms.
The determination of mutation load in muscle is a quite
invasive diagnostic tool for family testing and does not lead to
clear results. The cut-off between affected and non-affected is
not yet known. In our family, we found mutation loads in
muscle of clinically and biochemically unaffected individuals
up to 45%. The value of mutation load of other, more easily
available tissues, such as hair, buccal swab, and blood, are of
questionable value as bad correlations with muscle have been
described (van den Bosch et al. 2004). In our study, however,
we found less variability of mutation load in extra muscular
tissues (blood, buccal swab, and hair) and skeletal muscle. In
our index patient the mutation load was significantly lower
in fibroblasts. Confirmation of this finding by other studies is
necessary before it can be used as a predictive value for
counseling.
The best existing diagnostic tool is probably OXPHOS
analysis in M. quadriceps biopsy, as normal complex I
activity seems to exclude the disease. However, it remains an
invasive procedure offered in only a few specialized
laboratories. Reliable results depend on correct sampling,
optimal storage, and transport conditions, and laboratory
analytical experience.
Prerequisites for prenatal diagnosis of mtDNA point
mutations have been formulated by Poulton and Trunbull
(2000). First, a close correlation between mutation load and
disease manifestation. This seems to be the case for the
tRNALeu(UUR) mutation m.3302A>G but we do not know
yet which is the minimal mutation load to become
symptomatic. Second, no significant time-dependent
changes in mutation load. There is so far no knowledge
about this point for the mutation m.3302A>G. And, third, a
uniform distribution of mutation load in different tissues. In
all reported cases, the mutation load for m.3302A>G was
significantly lower in fibroblasts than in muscle leading to
an approximately normal activity of complex I. This may
be misleading, assuming that metabolic enzyme activities in
amniocytes and chorionic villus sampling (CVS) show a
similar expression as fibroblasts. Prenatal OXPHOS ana-
lysis in CVS and amniocytes is commonly considered
reliable only for mitochondrial defects in nuclear genes.
Hence, prenatal diagnosis for tRNALeu(UUR) m.3302A>G
mutation seems to remain very difficult. Pre-implantation
genetic diagnosis may represent the best management
option for many mtDNA diseases in the future but is
nowadays only available in some countries and on a
research basis. This approach, however, cannot guarantee
that the fetus will be unaffected; it needs CVS and/or serial
amniocentesis to confirm that the load of mutant mtDNA
remains low or undetectable along the pregnancy, a
condition that greatly improves the probability of an
unaffected offspring (Poulton et al. 2009).
Our results give an important insight into the
correlation between mutant heteroplasmy, complex I
activity, and clinical symptoms in the tRNALeu(UUR)
m.3302A>G mutation. The early and severe manifestation
of the disease in our index patient further broadens the
clinical spectrum associated with the tRNALeu(UUR) muta-
tion m.3302A>G. Mutation loads higher than 45% in
muscle are most probably necessary for complex I
deficiency to develop, leading to clinical manifestation.
These findings as well as heteroplasmy consistency
through many tissue types represent valuable information
for family members seeking accurate genetic, prognostic,
and reproductive counseling.
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